The Committee is responsible for preparing the European Medicines Agency’s (EMA) opinions on all questions concerning medicinal products for human use, in accordance with Regulation (EC) No 726/2004.

has granted Orphan Medicinal Product Designation (OMPD) to elraglusib, a novel GSK-3β inhibitor, for the treatment of pancreatic ductal adenocarcinoma (PDAC). “With limited treatment options ...